Sagimet Biosciences has secured United States Food and Drug Administration clearance to begin a registrational Phase 3 trial of denifanstat in moderate-to-severe acne, removing the final regulatory condition that had been holding the company’s newly focused dermatology strategy from entering pivotal U.S. testing. The FDA issued a Study May Proceed letter following clearance of the Investigational New Drug application, allowing Sagimet Biosciences to move ahead with an approximately 800-patient study expected to begin during the second half of 2026. About 450 participants are expected to be adolescents between 12 and 17 years old, giving the trial substantial exposure to the age group most heavily affected by acne. The milestone is especially important because denifanstat has already produced positive Phase 3 efficacy and longer-term safety findings in China, meaning the coming U.S. study will test whether those results can be reproduced within the regulatory framework required for a potential American approval.
The U.S. program will evaluate oral denifanstat at 50 milligrams once daily against placebo for 12 weeks, followed by a 40-week open-label extension assessing longer-term safety. Patients will be randomized two-to-one between active treatment and placebo, while three co-primary endpoints will assess global acne improvement and changes in inflammatory and non-inflammatory lesion counts. Sagimet Biosciences intends to begin dosing patients this year and has already built enough financial capacity to support the program through the expected Phase 3 readout and a potential New Drug Application submission.
Denifanstat enters U.S. Phase 3 with unusually substantial late-stage evidence already available
Denifanstat is entering its American pivotal trial with more efficacy evidence than would normally accompany a newly cleared U.S. acne program because Sagimet Biosciences’ Chinese licensing partner, Ascletis BioScience, has already completed a randomized Phase 3 study involving 480 patients with moderate-to-severe acne. Participants received either denifanstat 50 milligrams once daily or placebo for 12 weeks, using endpoints broadly aligned with those planned for the new United States trial.
Treatment success, defined as an Investigator’s Global Assessment score of clear or almost clear together with at least a two-point improvement from baseline, was achieved by 33.2% of denifanstat-treated patients compared with 14.6% receiving placebo. Total lesion counts fell 57.4% with denifanstat versus 35.4% with placebo, while inflammatory lesions declined 63.5% compared with 43.2%. Non-inflammatory lesion counts decreased 51.9% with denifanstat and 28.9% with placebo. Every reported primary and secondary efficacy endpoint met statistical significance, with p-values below 0.0001.
Those results provide a meaningful benchmark for the U.S. trial but cannot substitute for it. Different populations, clinical sites and regulatory expectations can produce different outcomes, and the American trial will include a substantial adolescent cohort. Replicating the China efficacy profile in roughly 800 U.S. patients would significantly strengthen the argument that fatty acid synthase inhibition provides a reproducible acne treatment mechanism rather than an isolated regional result.
Longer-term evidence from China also supports the decision to carry treatment beyond the initial 12-week assessment. A 40-week open-label Phase 3 extension enrolled 240 participants receiving denifanstat 50 milligrams daily, resulting in as much as 52 weeks of cumulative exposure for patients who had originally received active treatment. Sagimet Biosciences said denifanstat remained generally well tolerated and that efficacy measures continued improving beyond the initial 12-week period.
FASN inhibition gives denifanstat a differentiated approach to acne rather than another variation on existing therapy
Denifanstat is a selective inhibitor of fatty acid synthase, or FASN, an enzyme involved in producing fatty acids including palmitate. Sagimet Biosciences is targeting the pathway because FASN activity contributes to lipid synthesis and sebum production, which can play an important role in acne development. Company research has shown that its FASN inhibitors reduce de novo lipid synthesis in human sebocytes, the cells responsible for producing sebum in sebaceous glands.
The mechanism gives Sagimet Biosciences an opportunity to position denifanstat as more than another formulation of a familiar acne treatment. The company is developing the medicine as a once-daily oral therapy for moderate-to-severe disease, a population that can require repeated or prolonged treatment when topical medicines and other approaches do not provide sufficient control. Sagimet Biosciences estimates that approximately 50 million Americans experience acne each year and roughly 10 million have moderate-to-severe disease.
A novel mechanism does not automatically translate into commercial differentiation. Denifanstat must demonstrate that its lesion-count reductions, global treatment-success rate and longer-term tolerability offer physicians a sufficiently compelling reason to incorporate another systemic medicine into treatment pathways. The coming Phase 3 trial is particularly important because its large adolescent population will provide a clearer safety profile in patients likely to represent an important part of the eventual commercial market if the drug is approved.
The 40-week open-label extension will consequently matter almost as much as the 12-week efficacy readout. Acne frequently requires chronic management, so regulators and dermatologists will need confidence that sustained FASN inhibition remains tolerable over longer exposure. The prior Chinese extension is encouraging, but a large U.S. safety database will provide more relevant evidence for an eventual FDA submission.
Sagimet’s $175 million financing removes much of the immediate funding risk around Phase 3
Sagimet Biosciences enters the pivotal program from a much stronger financial position than it held at the beginning of 2026. The company completed a $175 million gross equity financing in April and reported $257.6 million in cash, cash equivalents and marketable securities at June 30. Management expects those resources to fund current operations through 2028, including the denifanstat Phase 3 readout and a potential NDA submission.
That runway materially reduces the financing risk around the pivotal acne program. Many clinical-stage biotechnology companies must raise capital during Phase 3, potentially creating dilution or leaving trial execution vulnerable to poor market conditions. Sagimet Biosciences has already raised much of the capital it expects to require for the denifanstat study, allowing the clinical result rather than near-term liquidity to become the primary determinant of the program’s value.
Second-quarter research and development expenses increased to $11.5 million from $7.2 million a year earlier as the company prepared its dermatology programs for expanded clinical development. Sagimet Biosciences posted a quarterly net loss of approximately $14 million, while current liabilities stood at just $5.4 million against total assets of approximately $263.4 million at the end of June.
The balance sheet also supports a second FASN inhibitor, TVB-3567, which is undergoing first-in-human Phase 1 testing. Subject to regulatory discussions and completion of that study, Sagimet Biosciences plans to begin a Phase 2 acne trial of TVB-3567 before the end of 2026 and is separately developing a topical FASN inhibitor strategy. This increasingly makes denifanstat the lead validation test for a broader dermatology platform rather than a standalone drug program.
SGMT shares remain subdued as investors wait for U.S. efficacy rather than regulatory clearance
Sagimet Biosciences shares were trading around $9.35 during the August 13 session, down approximately 0.4% from the previous close after reaching an intraday high near $9.67. The company’s market capitalization was approximately $497 million.
The muted response suggests investors largely expected IND clearance after Sagimet Biosciences had already disclosed plans to begin the study during the second half of 2026. The FDA letter removes regulatory uncertainty around trial initiation, but it does not change the principal valuation question, which is whether the positive Chinese Phase 3 efficacy profile will be repeated in the much larger United States program. This interpretation is an inference from the stock movement rather than a confirmed explanation from market participants.
Sagimet Biosciences’ roughly $257.6 million cash and investment position represents more than half of its current market capitalization, giving the company a relatively strong financial foundation for a pivotal-stage biotechnology business. Investors are therefore assigning meaningful but still cautious value to denifanstat and the broader FASN platform beyond the existing cash balance.
The FDA Study May Proceed letter marks a genuine transition for denifanstat. Sagimet Biosciences no longer needs to demonstrate that its planned U.S. Phase 3 design is acceptable enough to begin testing. It now has to show that an oral FASN inhibitor can reproduce the lesion reductions and treatment-success improvements seen in China across approximately 800 American adolescents and adults while maintaining an acceptable long-term safety profile. If that happens, denifanstat could move from a differentiated dermatology experiment toward a credible new systemic option for moderate-to-severe acne.
